Using a transgenic murine model of FOXM1 overexpression, we provide proof of concept that FOXM1 overexpression induces resistance to the AML chemotherapy backbone cytarabine (Figure 2). The gene discussed is FOXM1; the disease is acute myeloid leukemia.